Learn more about whether Bitdeer Technologies Group or Vertex, Inc. is a better investment based on AAII's A+ Investor grades ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Simultaneously, these higher costs can lead to cuts in business investment and consumer spending, potentially slowing economic growth and leading to layoffs—the very definition of stagflation.

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Artificial Intelligence isn’t pushing IP boundaries anymore. It’s smashing them. The film and music industries are bracing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The U.K. Supreme Court ruled Wednesday that a woman is someone born biologically female, excluding transgender people from ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

College of Mathematics and Statistics, Fujian Normal University, Fuzhou, Fujian 350117, P. R. China Center for Applied Mathematics of Fujian Province (Fujian Normal University), Fuzhou, Fujian 350117, ...